Command Palette

Search for a command to run...

Preprint WatchStrongSeptember 19th, 2026

Pan-B-Lineage Targeting with Adapter CAR-T Cells Controls Antigen-Heterogeneous Lymphoma

Krost, S.; Mast, A.-S.; Atar, D.; Kristmann, B.; Scheuermann, S.; Seitz, C. M.

Adapter CAR-T cells redirected simultaneously to CD19, CD20 and CD38 controlled an antigen-heterogeneous Burkitt lymphoma model in vitro and in vivo, whereas single-antigen targeting selected antigen-negative escape populations.

Strong contradiction

3 prior failures

Three or more documented clinical failures match this mechanism, or a Phase 3 efficacy failure is on record.

This preprint argues that antigen escape, not insufficient potency, is the limiting problem for CD19-directed cell therapy, and answers it with simultaneous CD19, CD20 and CD38 redirection through a single adapter CAR-T platform. Three CD19 programmes are on file in Claidex and none of them failed for lack of cytotoxicity. LY3541860 in rheumatoid arthritis (ly3541860-cd19-rheumatoid-arthritis-phase2a-efficacy-failure) failed on efficacy in an autoimmune setting where B-cell depletion was achieved, and both KYV-101 studies, in refractory lupus nephritis (kyv-101-cd19-car-t-refractory-lupus-nephritis-kysa-1-strategic-reprioritization) and diffuse cutaneous systemic sclerosis (kyv-101-cd19-car-t-diffuse-cutaneous-systemic-sclerosis-kysa-5-strategic-reprioritization), ended on sponsor reprioritization rather than on antigen biology. The flag is therefore about scope. Broadening the antigen set addresses relapse in oncology, and it does nothing for the two failure modes the Claidex record actually holds against CD19, which are indication selection in autoimmunity and portfolio economics. Teams citing this work as de-risking CD19 platforms should say which of the three failures it is meant to answer.

Abstract excerpt

Antigen heterogeneity and antigen-negative relapse represent major limitations to durable CAR-T cell efficacy in B-lineage malignancies. We previously developed the Adapter CAR-T cell (AdCAR-T) platform, which enables flexible redirection of engineered T cells to distinct surface antigens through biotinylated adapter molecules (AMs). In this study, AMs generated from an in-house-produced tafasitamab biosimilar (anti-CD19), commercial rituximab (anti-CD20), and an in-house-produced daratumumab biosimilar (anti-CD38) mediated potent, antigen-specific AdCAR-T cell cytotoxicity. While single-antigen targeting resulted in the selection of antigen-negative tumor populations, simultaneous targeting of CD19, CD20, and CD38 effectively controlled a defined heterogeneous Burkitt lymphoma model in vitro and induced sustained tumor control in vivo. Selective loss of the CD38+ AdCAR-T cell population after CD38-directed AM exposure was consistent with fratricide; however, the surviving CD38low population retained cytotoxic activity. These findings establish combinatorial AdCAR-T cell targeting as a flexible pan-B-lineage strategy for addressing pre-existing antigen heterogeneity and support further development of antibody-derived AM combinations for B-cell malignancies.

Matching Claidex post-mortems

3 of 3 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.